|Bid||25.36 x 200|
|Ask||25.95 x 200|
|Day's range||25.60 - 26.58|
|52-week range||13.12 - 29.20|
|PE ratio (TTM)||N/A|
|Earnings date||6 Nov 2017 - 10 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||33.21|
Healthcare won't be the same in the future because of these pioneers in gene editing, gene sequencing, and artificial intelligence.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 64 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...
Bluebird toppled to a four-week low Monday as an analyst downgraded the stock on doubts regarding its sickle cell disease drug.
The University of California is appealing a U.S. patent ruling over the game-changing gene editing technology known as CRISPR that favored the Broad Institute, a research affiliate of Harvard University and the Massachusetts Institute of Technology. The appeal filed in the U.S. Court of Appeals for the Federal Circuit was announced Thursday by the UC, the University of Vienna and handful of startup companies that have licensed its patents. Microbiologists Jennifer Doudna of the University of California, Berkeley, and Emmanuelle Charpentier of the University of Vienna were first to apply for patent in 2012 after discovering how the primitive bacterial system called CRISPR-Cas9 could be used to edit genomes in simple pieces of DNA (Frankfurt: 24D.F - news) called plasmids.